z-logo
open-access-imgOpen Access
Comparison the Efficacy of Fluconazole and Terbinafine in Patients with Moderate to Severe Seborrheic Dermatitis
Author(s) -
Narges Alizadeh,
Hamed Monadi Nori,
Javad Golchi,
Shahriar Sadr Eshkevari,
Ehsan Kazemnejad,
Abbas Darjani
Publication year - 2014
Publication title -
dermatology research and practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 29
eISSN - 1687-6113
pISSN - 1687-6105
DOI - 10.1155/2014/705402
Subject(s) - seborrheic dermatitis , medicine , fluconazole , dermatology , terbinafine , antifungal , itraconazole
Background . Topical agents can be unpleasant due to long-term therapies in patients with moderate to severe seborrheic dermatitis. Systemic antifungal therapy is another alternative in treatment. Aim . This study was conducted to compare the efficacy of oral fluconazole and terbinafine in the treatment of moderate to severe seborrheic dermatitis. Methods . 64 patients with moderate to severe seborrheic dermatitis (SD) were enrolled in a randomized, parallel-group study. One study group took terbinafine 250 mg daily ( n = 32) and the other one fluconazole 300 mg ( n = 32) weekly for four weeks. Seborrheic dermatitis area severity index (SDASI) and the intensity of itching were calculated before, at the end of treatment, and two weeks after treatment. Results . Both drugs significantly reduced the severity of seborrheic dermatitis ( P < 0.001). Multivariate linear regression revealed that efficacy of terbinafine is more than fluconazole ( P < 0.01, 95% CI (0.63–4.7)). Moreover, each index of SD severity reduced 0.9 times after treatment. ( P < 0.002, 95% CI (0.8–1.02)). The itching rate significantly diminished ( P < 0.001); however, there was no difference between these two drugs statistically. Conclusions . Both systemic antifungal therapies may reduce the severity index of SD. However, terbinafine showed more reduction in the intensity of the disease. In other words, the more the primary intensity of the disease is, the more its reduction will be. This trial is resgistered with 201102205871N1 .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom